Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.55 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.55 |
| ▸ | PDE5A | O76074 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174915 | 0.89 | ADORA3 (0.82) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL30507540 | 0.89 | ADORA3 (0.82) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL18496418 | 0.88 | ADORA3 (0.81) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5765138 | 0.88 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL17510179 | 0.88 | ADORA3 (0.64) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL173783 | 0.86 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL460864 | 0.86 | ADORA3 (0.68) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5763523 | 0.85 | ADORA3 (0.70) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL175323 | 0.85 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL460196 | 0.85 | ADORA3 (0.69) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012010577-A1 | SUBSTITUTED OXAZOLIDINONES AND OXAZINANONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | WO | disclosed |
| US-7173037-B2 | Carbamate-substituted pyrazolopyridines | BAYER HEALTHCARE AG (DE) | 2007-02-06 | — | — | US | disclosed |
| EP-1682182-A1 | NOVEL COMBINATION CONTAINING A STIMULATOR OF SOLUBLE GUANYLATE CYCLASE AND A LIPID-LOWERING SUBSTANCE | Bayer HealthCare AG (DE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1506193-B1 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | BAYER HEALTHCARE AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20060052397-A1 | Compounds for trearment of cardiovascular disorders and hypotensive agents | BAYER HEALTHCARE AG (DE) | 2006-03-09 | — | — | US | disclosed |
| WO-2005046725-A1 | NOVEL COMBINATION CONTAINING A STIMULATOR OF SOLUBLE GUANYLATE CYCLASE AND A LIPID-LOWERING SUBSTANCE | BAYER HEALTHCARE AG (DE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052397-A1 | Compounds for trearment of cardiovascular disorders and hypotensive agents | PDE3A, PDE3B, PDE2A | ADORA3 221/4885KCNH2 917/4885GUCY1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.